Page 168 - Aet News Today

Holon Solutions CEO Jon Zimmerman thinks more payers should invest in new technology to improve workloads for healthcare workers. The burnout crisis is too big for providers to solve by themselves, and many of the economic incentives for driving quality and efficiency in healthcare are housed within health plans and accountable care organizations, he said.

Of the more than 15% of American adults who have past-due medical debt, about 73% owe some or all of the money to hospitals, according to a recent Urban Institute report. The American Hospital Association said short-term limited duration health plans and high-deductible health plans are to blame.

GrayMatters Health recently received 510(k) clearance from the FDA to market its flagship product, which is a self-neuromodulation digital therapy for PTSD. The device uses neurofeedback on specific biomarkers to help patients identify and utilize their own mental strategy for lowering their emotional response.

A bipartisan group of House representatives introduced the Drug Price Transparency in Medicaid Act on Friday. The bill would ban spread pricing in Medicaid programs.

Zus Health — Jonathan Bush's health data platform that provides patient information at the point of care — recently closed a $40 million funding round. It also announced a partnership with Elation Health, a company that sells its EHR and other technology solutions to primary care providers. Elation will be integrating Zus' API into its own data collaboration systems.

BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it's on track for a Phase 3 test in non-small cell lung cancer.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

Tapping into community pharmacy can bring water to these rural healthcare deserts. Studies show that nine in ten Americans live within five miles of a pharmacy and high-risk patients visited their community pharmacy an average of 35 times per year, compared to four visits to their primary care provider and nine visits to specialists.

Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.

Providence recently launched a program to expand its patients’ access to in-home physical therapy. The health system is launching the initiative in partnership with Luna, a provider of in-home outpatient physical therapy that serves patients in nearly 30 states.